IMEZELF Trademark

Trademark Overview


On Tuesday, October 15, 2019, a trademark application was filed for IMEZELF with the United States Patent and Trademark Office. The USPTO has given the IMEZELF trademark a serial number of 88654260. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 15, 2023. This trademark is owned by Pfizer Inc.. The IMEZELF trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for treatment of alopecia; pharmaceutical preparations for treatment of vitiligo; pharmaceutical preparations for treatment of inflammatory bowel disease
imezelf

General Information


Serial Number88654260
Word MarkIMEZELF
Filing DateTuesday, October 15, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 15, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 18, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for treatment of alopecia; pharmaceutical preparations for treatment of vitiligo; pharmaceutical preparations for treatment of inflammatory bowel disease

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 18, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events


Event DateEvent Description
Monday, May 15, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 15, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 3, 2022SOU EXTENSION 5 GRANTED
Tuesday, September 20, 2022SOU EXTENSION 5 FILED
Sunday, October 2, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 20, 2022TEAS EXTENSION RECEIVED
Thursday, March 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 22, 2022SOU EXTENSION 4 GRANTED
Tuesday, March 22, 2022SOU EXTENSION 4 FILED
Tuesday, March 22, 2022TEAS EXTENSION RECEIVED
Thursday, September 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 28, 2021SOU EXTENSION 3 GRANTED
Tuesday, September 28, 2021SOU EXTENSION 3 FILED
Tuesday, September 28, 2021TEAS EXTENSION RECEIVED
Thursday, March 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 16, 2021SOU EXTENSION 2 GRANTED
Tuesday, March 16, 2021SOU EXTENSION 2 FILED
Tuesday, March 16, 2021TEAS EXTENSION RECEIVED
Saturday, August 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 27, 2020SOU EXTENSION 1 GRANTED
Thursday, August 27, 2020SOU EXTENSION 1 FILED
Thursday, August 27, 2020TEAS EXTENSION RECEIVED
Tuesday, April 14, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 18, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 18, 2020PUBLISHED FOR OPPOSITION
Wednesday, January 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 9, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 8, 2020ASSIGNED TO EXAMINER
Friday, October 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 18, 2019NEW APPLICATION ENTERED